Evommune to Present Positive Phase 2a EVO301 Data at EADV; Phase 2b Set for Mid-2027
EVMN is trading near its 52-week low of $8.69 (0.9% above the low).
Summary
Evommune announced positive Phase 2a top-line data for EVO301 in atopic dermatitis, with a late-breaking presentation at EADV on October 1, 2026, and a Phase 2b study planned for mid-2027.
Key Events · Product Development and Regulatory · EVMN
-
Positive Phase 2a EVO301 Data
Press release confirms positive top-line data from the Phase 2a proof-of-concept trial of EVO301 in moderate-to-severe atopic dermatitis.
-
Late-Breaker at EADV 2026
Data will be presented in a late-breaking oral session on October 1, 2026, at the EADV Congress in Vienna (4:30–4:45 pm CEST).
-
Phase 2b Timing
Phase 2b dose-ranging study for EVO301 in moderate-to-severe AD is anticipated to begin in mid-2027.
-
Pipeline Pivot After EVO756 Failures
Follows EVO756's Phase 2b failures in chronic spontaneous urticaria (June 2026) and atopic dermatitis (September 2026); EVO301 is now the lead asset.
Analysis · EVMN · Life Sciences
Evommune is pivoting to EVO301 after EVO756 failed two Phase 2b trials this year. The press release confirms positive top-line Phase 2a data for EVO301 in atopic dermatitis and schedules a late-breaking oral presentation at EADV on October 1, 2026. A Phase 2b dose-ranging study is anticipated to begin in mid-2027. This is the first concrete validation of the company's remaining lead asset, and it arrives while the stock trades near its 52-week low of $8.69.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1495 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $8.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $318.3M. The 52-week trading range was $8.69 to $33.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.